GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Context Therapeutics
Context Therapeutics is a clinical-stage biotech company developing therapies for solid tumors, with a particular focus on women's cancers. Its stock price is highly volatile, as the company's value depends almost entirely on news about the clinical trials of its key drugs.
Share prices of companies in the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women, such as breast and ovarian cancer. We've classified it in the "Cancer Women" segment. The chart below shows the overall dynamics in this important oncology sector, where new treatment approaches are being sought.
Broad Market Index - GURU.Markets
Context Therapeutics is an oncology company developing drugs to treat hormone-dependent cancers in women. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Context shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CNTX - Daily change in the company's share price Context Therapeutics
Context Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies focused on women's cancer. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer women
Context Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies focused on women's cancer. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment tool.
Daily change in the price of a broad market stock, index - GURU.Markets
Context Therapeutics is a biotech company focused on women's health, particularly cancer treatment. Its shares are highly volatile and dependent on clinical trial results. These scientifically based movements are part of the complex picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Context Therapeutics
Context Therapeutics' year-over-year performance tells the story of its strategic pivot into oncology. Its market cap change over the past 12 months reflects its decision to focus on developing a single, highly promising cancer drug, its new bet for the future following a review of its clinical pipeline.
Annual dynamics of market capitalization of the market segment - Cancer women
Context Therapeutics is a clinical-stage biotech focused on cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Context Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Context Therapeutics
Context Therapeutics is a clinical-stage oncology company focused on hormone-dependent tumors. Its monthly performance is entirely determined by news from its clinical programs. Data from its lead drug trials is the primary driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Cancer women
Context Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for hormone-dependent cancers in women. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its research, focused on new therapeutic targets, is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Context Therapeutics is a biotech company focused on treating hormone-dependent cancers in women. Its shares move at their own pace, driven by news of clinical trials. The correlation with overall market trends is minimal, as investors evaluate scientific potential rather than macroeconomic indicators.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Context Therapeutics
Context Therapeutics, a biotech focused on treating women's cancers, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials and partnerships, reflecting the risks and hopes in this important area of oncology.
Weekly dynamics of market capitalization of the market segment - Cancer women
Context Therapeutics focuses on developing drugs for women's cancers. This chart separates its clinical data-driven volatility from the overall fluctuations in the cancer sector, highlighting how unique its scientific path is.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Context Therapeutics is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that CNTX's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
CNTX - Market capitalization of the company Context Therapeutics
The Context Therapeutics chart is a financial map of the fight against hormone-dependent cancers in women. This biotech company's market cap reflects the hopes for its drugs targeting breast and ovarian cancer. Its dynamics are a barometer of progress in clinical trials and confidence in its approach to treating these diseases.
CNTX - Share of the company's market capitalization Context Therapeutics within the market segment - Cancer women
Context Therapeutics's oncology presence is focused on the treatment of hormone-dependent cancers in women. Its market share is driven by the potential of its clinical programs aimed at developing new drug combinations to combat breast and ovarian cancer.
Market capitalization of the market segment - Cancer women
Context Therapeutics is a biotech company focused on treating women's cancers. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the enormous investment and hopes associated with the discovery of new treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Context Therapeutics is a biopharmaceutical company focused on developing treatments for women's cancers. Its market capitalization reflects its niche strategy. The chart below shows the economic weight of companies working in this important field.
Book value capitalization of the company, segment and market as a whole
CNTX - Book value capitalization of the company Context Therapeutics
Context Therapeutics is an early-stage biopharmaceutical company. Its book value is primarily cash from investors. The chart below shows how this capital is spent on preclinical research. This is its financial "headroom."
CNTX - Share of the company's book capitalization Context Therapeutics within the market segment - Cancer women
Context Therapeutics is a clinical-stage biotech company focused on women's oncology. Its value lies in its scientific platform. Its tangible asset share will be minimal, typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Cancer women
Context Therapeutics is a biotech company whose value is created in laboratories developing cancer treatments. It's a "lightweight" model, driven by science. The chart below illustrates the extent to which the pharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Context Therapeutics' balance sheet represents capital focused entirely on developing drugs for the treatment of hormone-dependent cancers in women. The book value chart shows the amount of resources devoted to this important and specific area of oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Context Therapeutics
Context Therapeutics is a biotech company focused on treating hormone-dependent cancers in women. It has no tangible assets. Its market capitalization is a bet on its scientific approach and drug candidates. The chart illustrates the risks and hopes associated with developing new cancer treatments.
Market to book capitalization ratio in a market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on women's cancer. It has no commercial products. Its value is a bet on the success of its clinical development. The chart shows the significant premium investors pay for the hope of developing a new drug.
Market to book capitalization ratio for the market as a whole
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat women's cancers. The chart shows how the market values the company, which targets specific oncological diseases, its market capitalization reflects the success of its clinical programs and the potential of its drugs in this important area of medicine.
Debts of the company, segment and market as a whole
CNTX - Company debts Context Therapeutics
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat gynecological cancers. While in clinical trials, the company uses raised capital to fund its expensive and risky R&D programs, as reflected in the financial strategy in this chart.
Market segment debts - Cancer women
Context Therapeutics is a biopharmaceutical company specializing in developing drugs to treat hormone-dependent cancers in women. This is a key area of oncology. The chart shows the general financial metrics for the biotech sector, against which Context is raising capital to conduct clinical trials of its targeted drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Context Therapeutics
Context Therapeutics is a biotech company focused on hormone-dependent cancers in women. Developing targeted therapies is a long and risky process. This chart shows the role debt plays in funding its research, allowing investors to assess the company's financial vulnerability to potential success.
Market segment debt to market segment book capitalization - Cancer women
Developing drugs to treat hormone-dependent cancers in women, a focus of Context Therapeutics, is a key area of oncology. This chart shows how the biotech sector funds its research. It allows one to appreciate how Context's financial model, which is currently in clinical trials, differs from that of large pharmaceutical companies with approved drugs.
Debt to book value of all companies in the market
Context Therapeutics focuses on developing drugs to treat gynecological cancers. This is a highly specialized area of biotechnology that requires significant capital for research. The chart allows us to assess how their debt strategy compares to the broader pharmaceutical market.
P/E of the company, segment and market as a whole
P/E - Context Therapeutics
This chart shows the valuation of Context Therapeutics, a biopharmaceutical company focused on treating hormone-dependent cancers in women. For a clinical-stage company, its value is determined not by profits, but by the potential of its scientific developments to offer new therapeutic options.
P/E of the market segment - Cancer women
This indicator represents the average valuation for the biotech sector in which Context Therapeutics operates. It reflects the overall level of investor optimism regarding scientific breakthroughs in oncology. The chart provides a benchmark for understanding how the market values Context's niche developments.
P/E of the market as a whole
Context Therapeutics is a biotech company specializing in the treatment of hormone-dependent cancers in women, such as breast and ovarian cancer. Its valuation depends on the success of clinical trials. This chart shows the overall interest in oncology. It helps understand how the market views Context's scientific approach and its potential in this important but competitive therapeutic area.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Context Therapeutics
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women, such as breast and ovarian cancer. The company's future depends on the success of its clinical programs. This schedule reflects investor expectations regarding its scientific approach and the potential of its drugs in this important area of oncology.
%20P%2FE%20Context%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Context-Therapeutics&v=1772612111083 "Chart of the company's future (projected) P/E Context Therapeutics")
Future (projected) P/E of the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This is an important and complex area of oncology. This chart reflects expectations for the biotech sector, providing context for assessing how the market views Context's scientific approach and developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772612111129 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This chart of overall expectations illustrates investor sentiment toward niche areas of oncology. Market optimism and a willingness to fund research are essential for attracting capital for research aimed at improving treatment outcomes for specific patient groups.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612111204 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Context Therapeutics
Context Therapeutics is a biopharmaceutical company focused on the treatment of hormone-dependent cancers in women. This chart shows the company's financial performance at the clinical stage. Future profitability depends on the success of its targeted drugs in clinical trials and their potential combination with existing treatments.
Profit of companies in the market segment - Cancer women
Vince Holding Corp. is a contemporary luxury clothing brand. Its profitability depends on fashion trends and its ability to compete in the premium segment. This chart reflects the challenges of the fashion industry, where a strong brand is essential, but maintaining relevance and managing inventory amid changing tastes is a constant struggle for profitability.
Overall market profit
Context Therapeutics is a biotech company focused on developing drugs to treat hormone-dependent cancers in women. Currently in clinical trials, its value is determined by the scientific potential of its developments. It is an example of a business whose trajectory can change dramatically following the publication of data.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Context Therapeutics
Context Therapeutics is a biotech company focused on developing drugs to treat hormone-dependent cancers in women. Its profit outlook is long-term and depends on the success of clinical trials. This chart shows analyst expectations for its scientific developments and their potential in oncology.
%20profit%20of%20the%20company%20Context%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Context-Therapeutics&v=1772612111608 "Graph of future (projected) profit of the company Context Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women, such as breast and ovarian cancer. This chart shows revenue projections for the oncology sector. It reflects the need for new treatments targeting the specific mechanisms of women's cancers.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772612111633 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
Context Therapeutics is a biopharmaceutical company specializing in the treatment of hormone-dependent cancers in women. Its success depends on the results of clinical trials. The overall economic outlook, reflected in this chart, influences the investment climate and the strategic decisions of large pharmaceutical companies that are potential partners.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612111638 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Context Therapeutics
Context Therapeutics is a biotech company focused on developing drugs to treat hormone-dependent cancers in women. Currently in the clinical stage, it has no commercial revenue. The chart reflects investor assessments of its scientific approach and the potential of its developments to improve treatment outcomes for breast and ovarian cancer.
P/S market segment - Cancer women
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hormone-dependent cancers in women, such as breast and ovarian cancer. This chart shows the average valuation in the sector, allowing one to assess the market's perception of the revenue potential of Context's niche developments.
P/S of the market as a whole
Context Therapeutics is a biopharmaceutical company focused on developing treatments for hormone-dependent cancers in women. The company is currently in clinical trials. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Context Therapeutics
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This chart shows how investors assess the future potential of its developments. This assessment is based on expectations of successful clinical trials, which could lead to new treatments.
%20P%2FS%20Context%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Context-Therapeutics&v=1772612111728 "The graph of the company's future (projected) P/S Context Therapeutics")
Future (projected) P/S of the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company specializing in developing drugs to treat hormone-dependent cancers in women, such as breast and ovarian cancer. The chart shows how investors estimate Context's future sales, reflecting the potential of its targeted therapy in women's cancer.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772612111744 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
This graph reflects the hopes associated with the treatment of hormone-dependent cancers in women. Context Therapeutics develops drugs to improve the effectiveness of existing hormone therapy. Their work in this important area of oncology inspires confidence that new drug combinations will achieve improved outcomes for millions of patients worldwide.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612111769 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hormone-dependent cancers in women. Currently, the company has no commercial sales revenue. Its financial chart reflects revenue from collaborations and investments in its research.
Sales of companies in the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women, such as breast and endometrial cancer. This chart shows total revenue in the women's health sector. It illustrates the need for new treatments that target the specific biological mechanisms of female cancers.
Overall market sales
Context Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of hormone-dependent female oncologies. Being in the clinical stage, its value is determined by the potential of its scientific developments. This overall economic climate affects the availability of capital for funding highly specialized oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Context Therapeutics
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. Its future depends on the success of clinical trials. The chart shows analysts' speculative revenue forecasts, which are betting on a breakthrough in the treatment of breast and endometrial cancer.
%20sales%20of%20the%20company%20Context%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Context-Therapeutics&v=1772612111840 "Schedule of future (projected) sales of the company Context Therapeutics")
Future (projected) sales of companies in the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing treatments for hormone-dependent cancers in women, such as breast and ovarian cancer. Success depends on clinical data. This chart displays projected revenues for the entire women's health sector, providing insight into overall expectations for the oncology drug market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772612111854 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
Context Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of women's cancers. The company is currently in clinical trials, and its future depends on their success. This overall economic activity schedule impacts the availability of funding for the biotech sector to continue R&D.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612111897 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Context Therapeutics
Context Therapeutics is a biotech company focused on developing drugs for the treatment of gynecological cancers. This indicator reflects its financial progress through the clinical trial stage. It demonstrates the level of R&D investment required to bring new targeted drugs to market and achieve commercial success.
Market segment marginality - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing treatments for hormone-dependent cancers in women. Its financial performance reflects its focus on clinical trials. This chart provides an overview of the company's operating model compared to other companies in the field of women's oncology.
Market marginality as a whole
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. Their lead candidate targets the progesterone receptor. Their success depends on clinical trials. This overall profitability curve doesn't affect their scientific activities, but it is important for attracting investment.
Employees in the company, segment and market as a whole
Number of employees in the company Context Therapeutics
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. Being in the early clinical stage, it has a compact team. This graph shows the dynamics of the small scientific team conducting research in this highly specialized area of oncology.
Share of the company's employees Context Therapeutics within the market segment - Cancer women
Context Therapeutics focuses on developing drugs to treat hormone-dependent cancers in women. This chart shows the percentage of clinicians and scientists the company attracts in this specific area of oncology. Its team is working on developing new treatment options for breast and ovarian cancer.
Number of employees in the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This chart shows overall employment in the oncology sector. It illustrates how Context Therapeutics is working in an important niche, striving to create new treatment options for patients with breast and ovarian cancer.
Number of employees in the market as a whole
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This is an important and underserved area of oncology. This graph illustrates the labor market, where specialized biotech companies like Context are creating positions for scientists working on specific medical problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Context Therapeutics (CNTX)
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This chart is a prime example of biotech. The very high market capitalization per employee means that investors are pricing in the potential success of the drugs in clinical trials. Value is created by intellectual property.
%20of%20the%20company%20Context%20Therapeutics%20(CNTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Context-Therapeutics-CNTX&v=1772612112020 "Chart of market capitalization per employee (in thousands of dollars) of the company Context Therapeutics (CNTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
Context Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of women's cancers. Their value is determined by the potential of their clinical programs. This metric reflects the value the market places on their research. A high value reflects investors' bet on the success of their targeted therapy.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772612112038 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
Context Therapeutics is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. Its valuation is dependent on the success of clinical trials. This metric illustrates how investors evaluate the scientific potential in a very specific and important niche of oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612112046 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Context Therapeutics (CNTX)
Context Therapeutics (CNTX) is a clinical-stage biotech R&D company focused on treating women's cancers (ovarian and endometrial cancer). This is pure science. This metric measures their capital burn rate—the net loss (R&D expenses) per employee.
%20Chart%20Context%20Therapeutics%20(CNTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Context-Therapeutics-CNTX&v=1772612112076 "Company Profit Per Employee (in thousands of dollars) Chart Context Therapeutics (CNTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
Context Therapeutics is a clinical-stage biotech focused on treating cancer in women. As with other R&D firms, this timeline is a goal for the future. Currently, all value lies in the intellectual potential of their scientific team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772612112089 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
Context Therapeutics (CNTX) is a biotech company specializing in developing treatments for women's cancer. They are in the clinical stage. This chart shows that their current business is R&D expenses. Their profit per employee is negative, as their entire research team is working on future products.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612112121 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Context Therapeutics (CNTX)
For Context Therapeutics, a company focused on developing drugs to treat women's cancers, this graph reflects the clinical trial stage. Future revenue growth per employee depends on the success of its drug candidates and partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Context-Therapeutics-CNTX&v=1772612112135 "Sales chart per company employee Context Therapeutics (CNTX)")
Sales per employee in the market segment - Cancer women
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs to treat women's cancers. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their R&D team is in their narrow oncology niche compared to other biotechs.
Sales per employee for the market as a whole
Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on treating hormone-dependent cancers in women. Currently, its staff consists entirely of researchers. This metric is critical for CNTX: it's at zero. Its future growth will signal the success of its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Context Therapeutics (CNTX)
Context Therapeutics is an early-stage biotech focused on treating women's cancer. Its future depends entirely on success in clinical trials. This chart reflects investor bets that its scientific platform will fail, a common outcome for companies operating in this highly competitive oncology niche.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Context-Therapeutics-CNTX&v=1772612112165 "Short Shares Chart for the Company Context Therapeutics (CNTX)")
Shares shorted by market segment - Cancer women
Context Therapeutics (CNTX) is a biopharmaceutical company focused on developing drugs to treat women's cancers (breast and ovarian cancer). This chart shows the overall short position in the oncology biotech sector. It reflects the high risk and failure rate associated with developing new cancer drugs.
Shares shorted by the overall market
Context Therapeutics is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing CNTX will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Context Therapeutics (CNTX)
This oscillator for Context Therapeutics reflects binary bets in hormone-dependent cancers. The company targets breast and ovarian cancer treatments. This is a data-driven sector. Any positive signals from early-phase trials trigger euphoria and "overheating" (above 70). A key trial failure or toxicity concerns immediately send the stock plummeting (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Context-Therapeutics-CNTX&v=1772612112340 "RSI 14 indicator chart for the company's stock Context Therapeutics (CNTX)")
RSI 14 Market Segment - Cancer women
Context (CNTX) is a "biotech" company, a "hunter" for *women's* cancer. They develop *drugs* for *treating* breast and *ovarian* cancer. The "Cancer Women" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is CNTX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Context Therapeutics (CNTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CNTX (Context Therapeutics)
Context Therapeutics is a clinical-stage biotech focused on treating hormone-dependent cancers (such as breast cancer). This chart shows the average analyst price target. Their forecast is speculative and depends almost entirely on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CNTX-Context-Therapeutics&v=1772612112513 "A chart showing analyst consensus forecasts for the expected stock price. CNTX (Context Therapeutics)")
The difference between the consensus estimate and the actual stock price CNTX (Context Therapeutics)
Context Therapeutics (CNTX) is a biotech company focused on developing hormonal therapies for cancer (breast and ovarian). This chart is a barometer of their R&D. It measures the gap between the speculative price and the consensus target, reflecting the high (but risky) potential analysts see for success in their clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CNTX-Context-Therapeutics&v=1772612112587 "A chart showing the difference between the consensus forecast and the actual stock price. CNTX (Context Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer women
Context Therapeutics is a biotech company developing new treatments for female-specific cancers. This is high-risk R&D, where success depends on scientific breakthroughs. This chart shows analysts' overall expectations for the entire oncology sector. It reflects whether experts believe new breakthroughs are possible or whether they believe the biotech sector has entered a lull and funding decline.
Analysts' consensus forecast for the overall market share price
Context Therapeutics is a clinical-stage biotech focused on developing drugs to treat women's cancers. Like many biotechs without revenue, their valuation reflects expectations. This chart reflects the overall risk appetite in the market. When analysts are optimistic, investors are more willing to fund long-term, risky projects, such as Context's drug development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Context Therapeutics
Context Therapeutics is a clinical-stage biotech focused on developing drugs for hormone-dependent female cancers (breast and ovarian). This is a pure R&D bet. This chart is a summary indicator of the market's faith in their science. It doesn't reflect revenue, but rather a speculative assessment of their R&D progress, clinical trial data, and their chances of success in this complex field.
AKIMA Market Segment Index - Cancer women
Context Therapeutics (CNTX) is a biopharmaceutical company focused on developing drugs to treat hormone-dependent cancers in women. This is an area of high risk and potential breakthroughs. The chart shows the average index value for the segment. It helps investors assess how the market perceives the risks and potential of Context Therapeutics compared to the overall biotech industry.
The AKIM Index for the overall market
Context Therapeutics is a biopharmaceutical company specializing in women's health and the treatment of hormone-dependent cancers. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to the overall economic trends affecting oncology funding.
